Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer

Abstract The neuroendocrine differentiation in PC could potentially represent a new finding with diagnostic, prognostic and therapeutic implications. This study aimed at evaluating the clinical usefulness of CgA as a neuroendocrine (NE) serum-marker. We investigated the role of the serum concentrati...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gerontology and geriatrics 2009-03, Vol.48 (2), p.213-217
Main Authors: Malaguarnera, Michele, Cristaldi, Erika, Cammalleri, Lisa, Colonna, Valentina, Lipari, Helga, Capici, Alessandra, Cavallaro, Andrea, Beretta, Massimiliano, Alessandria, Innocenza, Luca, Salvatore, Motta, Massimo
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
Carbohydrate antigen (CA19-9)
Case-Control Studies
Chromogranin A
Chromogranin A - blood
Concentration
Differentiation
Female
Humans
Internal Medicine
Male
Neoplasm Staging
Neuroendocrine components
Neuroendocrine response
Pancreatic cancer
Pancreatic Neoplasms - blood
Pancreatitis, Chronic - blood
Prognosis
Serum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The neuroendocrine differentiation in PC could potentially represent a new finding with diagnostic, prognostic and therapeutic implications. This study aimed at evaluating the clinical usefulness of CgA as a neuroendocrine (NE) serum-marker. We investigated the role of the serum concentration of CgA in a study group of patients with PC. CgA was significantly higher in the patients affected by PC as compared with the group of healthy subjects (HS) and those with chronic pancreatitis (CHP) ( p < 0.001). Also the HS group differed significantly from the CHP control group in the serum CgA levels ( p < 0.001). The serum carbohydrate antigen (CA19-9) level displayed a significant difference ( p < 0.001) between the PC and the HS group. The PC and CHP groups, as well as the HS and CHP groups showed also significant differences in the CA19-9 levels ( p < 0.001). One can conclude that the patients with higher CgA levels had poorer prognosis and survival, as compared to those with lower CgA levels. These results support the notion that the determination of serum CgA level before treatment may be a potential prognostic factor for PC.
ISSN:0167-4943
1872-6976
DOI:10.1016/j.archger.2008.01.014